RDD Europe 2025, Co-Organized by Aptar Pharma and RDD Online, Celebrates 20 Years
Aptar Pharma, leader in respiratory drug delivery solutions, and RDD Online® are pleased to announce their co-organization of RDD® Europe 2025, which will be held in-person from Tuesday, May 6 to Friday, May 9, 2025 at the Estoril Congress Center in Estoril, Portugal.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250227163353/en/
RDD Europe 2025, Co-Organized by Aptar Pharma and RDD Online (Graphic: Business Wire)
Celebrating 20 years of RDD Europe and one of the largest and highly regarded international respiratory health conferences, RDD Europe 2025 will host over 500 scientists, engineers, clinicians and business professionals engaged in all aspects of nasal and pulmonary drug delivery.
With curated and peer reviewed content organized in six Knowledge Spaces, speakers, workshops, poster presenters and exhibitors will share timely, actionable insights under the following themes:
- Bench to Bedside: Emerging Therapies and Clinical Advances
- Inspiring Dry Powder Inhalation: Formulation Science and Device Design
- MDIs in Transition: Evolving Science and Regulations
- Advanced Inhalation: AI and Data Driven Design
- Aqueous Agenda: Soft Mist Inhalers and Nebulizer Advances
- Nasal Spotlight: Advances in Systemic and Nose-to-Brain Delivery.
Twelve delegate-selectable industry Workshops will take place on Wednesday, May 7, providing practical and interactive demonstrations of innovative technologies, products and capabilities in a small group setting.
An integrated Poster & Exhibition session will run throughout the 3-day conference, ensuring ample opportunity for networking, with 70 exhibit tables and 72 posters showcasing academic and industry research, and development breakthroughs across established and emerging nasal and pulmonary drug delivery platforms.
To complement in-person activities, RDD Europe 2025 will also include extended online access from April 29 to June 30, 2025 to on-demand presentations and company profiles. In addition, almost 3,000 peer-reviewed speaker and poster papers will be available to delegates for 12 months after the conference.
The conference will open with a Welcome Cocktail Reception on the evening of Tuesday, May 6, and Aptar Pharma will sponsor a Gala Dinner at a scenic location in Estoril on Thursday, May 8.
As a global leader in OINDP device design and technology, Aptar Pharma is proud to be a Co-Organizer of RDD Europe 2025 and will host a workshop on May 7. Entitled “Ready for Clinical Trials in 1 Hour: A Roadmap to Success,” this workshop will be co-presented by Jonathan Mulpas, Director Business Development Pulmonary Category, Aptar Pharma, Will Ganley, Manager, Computational Pharmaceutics, Nanopharm, an Aptar Pharma company, and Carolina Dantas, Head of Medical & Scientific Affairs, Pulmotree.
“Estoril is a great location to celebrate 20 years of RDD Europe conferences. I can’t wait to catch up with friends and organizations who have returned year after year since RDD Europe 2005 was first held in Paris,” commented Richard Dalby, one of the conference organizers. “So much has changed since then, and the innovation I’ve witnessed seems poised to have direct benefits on patient health, healthcare provider choice and environmental sustainability.”
Added Carolyn Penot, Director of Operational Marketing at Aptar Pharma, “RDD Europe 2025 is a must-attend event, and this year’s Knowledge Spaces will represent the latest thinking in nasal and pulmonary drug delivery. We look forward to celebrating 20 years of RDD Europe with our conference participants.”
To register as a delegate or learn more about sponsorship opportunities, visit the RDD Europe 2025 website.
About RDD Online
RDD Online manages the organization of Respiratory Drug Delivery conferences in the U.S., and partners with Aptar Pharma to run RDDevents in Europe and Asia. These international conferences, focused on technologies and solutions to improve patient health, routinely attract over 500 delegates from 25 countries representing academia, industry and regulatory agencies. RDD Online also supplies realistic mouth throat models, Nephele mixing inlets and dose collection tubes. We offer scientific and technical publications, web-based training, and a company directory of organizations active in pulmonary and nasal drug delivery. For more information, please visit www.rddonline.com.
About Aptar Pharma
Aptar Pharma is part of AptarGroup, Inc., a global leader in the design and manufacturing of a broad range of drug delivery, consumer product dispensing and active material science solutions and services. Aptar’s innovative solutions and services serve a variety of end markets including pharmaceutical, beauty, food, beverage, personal care and home care. Using insights, proprietary design, engineering and science to create dispensing, dosing and protective technologies for many of the world’s leading brands, Aptar in turn makes a meaningful difference in the lives, looks, health and homes of millions of patients and consumers around the world. Aptar is headquartered in Crystal Lake, Illinois and has approximately 13,000 dedicated employees in 20 countries. For more information, visit www.aptar.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250227163353/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SES: Q1 2025 Results30.4.2025 07:30:00 CEST | Press release
Solid Start to the Year SES S.A. announces financial results for the three months ended 31 March 2025. Revenue of €509 million (-0.5% yoy(1)) and Adjusted EBITDA(2) of €280 million (-0.9% yoy(1)), both growing excl. periodic impact Networks revenue up +8.4% yoy(1) including some periodic impact supported by growth in Government (+13.1% yoy(1)) and Mobility (+8.5% yoy(1)); Media (-10.6% yoy(1)) in-line with expectations €360 million of new business and contract renewals signed in Q1 2025 Net Leverage at 1.2x(3) (including cash & cash equivalents of €3.1 billion(4)) O3b mPOWER satellites 7&8 have reached final orbital position – boosting mPower network capacity and resilience from May FY 2025 financial outlook(5) on track with yoy stable Revenue and broadly stable Adjusted EBITDA re-affirmed Fully funded Intelsat acquisition anticipated to complete in H2 2025 – intention to optimise the combined debt structure On 3 April 2025, AGM approved all company recommended resolutions including pr
Geoswift Launches Visa Direct to Enhance Cross-Border Payment Offers in Over 30 Countries30.4.2025 03:00:00 CEST | Press release
Geoswift announced today the integration of Visa Direct with Geoswift's cross-border payments platform. Visa Direct facilitates payouts to more than 140 countries and territories. The integration will enable payouts in 32 countries and territories, across 13 currencies, covering major markets in Asia Pacific, North America, Europe and Middle East, with plans for more in the future. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250423288249/en/ Bryan Ma, SVP, Head of Geoswift Global Payments, and Swapnil Mhasde, Head of Visa Direct Commercialization and Solutions, Asia Pacific, celebrating the launch in Singapore. Geoswift is a leading provider of cross-border payment services and solutions globally. With over two decades of innovation, it has become a trusted name in B2B, education, eCommerce, remittance, and travel payment use cases. Raymond Qu, Group CEO of Geoswift, stated, "At Geoswift, our vision has always been to del
Logitech Announces Q4 and Full Fiscal Year 2025 Results29.4.2025 22:03:00 CEST | Press release
A Year of Broad-Based Sales Growth, Expanded Market Share and Increased Profitability, Driven by Strategic Priorities SIX Swiss Exchange Ad hoc announcement pursuant to Art. 53 LR — Logitech International (SIX: LOGN) (Nasdaq: LOGI) today announced financial results for the fourth quarter and full Fiscal Year 2025 ended March 31, 2025. For Fiscal Year 2025: Sales were $4.55 billion, up 6 percent in US dollars and 7 percent in constant currency, compared to the prior year. GAAP operating income was $655 million, up 11 percent compared to the prior year. Non-GAAP operating income was $775 million, up 11 percent compared to the prior year. GAAP earnings per share (EPS) was $4.13, up 7 percent compared to the prior year. Non-GAAP EPS was $4.84, up 14 percent compared to the prior year. Cash flow from operations was $843 million. The year-ending cash balance was $1.5 billion. The Company returned $797 million of cash to shareholders through its annual dividend payment and share repurchases.
U.S. Patent and Trademark Office Invalidates Pharmacyclics Patent Asserted Against BeiGene29.4.2025 21:32:00 CEST | Press release
BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced that the U.S. Patent and Trademark Office (USPTO) rendered a Final Written Decision invalidating all claims of Pharmacyclics LLC’s (Pharmacyclics) U.S. Patent No. 11,672,803 (the ‘803 patent) that were challenged by BeiGene in a post-grant review (PGR) proceeding. On November 1, 2023, BeiGene filed a PGR petition with the USPTO challenging the validity of certain claims of the ‘803 patent, in response to a patent infringement lawsuit Pharmacyclics brought against BeiGene concerning BRUKINSA® (zanubrutinib). On May 1, 2024, the USPTO granted BeiGene’s petition to institute the PGR. The USPTO’s Final Written Decision is appealable by Pharmacyclics. Commenting on the ruling, BeiGene General Counsel Chan Lee said: “We are pleased that the USPTO invalidated all challenged claims of the ‘803 patent. Today’s decision reinforces our belief th
One out of Three Secure Civil IDs Delivered Each Year Is Powered by Thales29.4.2025 16:50:00 CEST | Press release
In a world where identity fraud represents a critical vulnerability for citizens and societies, Thales is leading the transformation of civil identity into a secure and citizen-first service. Through its advanced Civil Identity Suite, Thales enables governments worldwide to protect their citizens, ensuring protection at every stage of the identity journey and for the entire identity chain. Supporting more than 300 national identity programmes and having enrolled over 500 million people, Thales is uniquely positioned to deliver secure and responsible identity solutions. Each year, Thales powers one in three smart civil IDs (official electronic documents) issued worldwide, highlighting the company’s key role in shaping the future of identities and helping governments and citizens transition smoothly to digital. With its Civil Identity Suite, Thalesenables the issuance and management of both physical and digital identities, as well as all means of enrolling citizens and enabling seamless
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom